Loading clinical trials...
Loading clinical trials...
The study start on January 18, 2017. The Severe(FⅧ\<1%) and moderate hemophilia A (FⅧ1%~5%)children with high titer inhibitor(historical peak inhibitor titer≥5BU ) combining with poor ITI risk(s) were...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Beijing Children's Hospital
NCT06312475 · Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
NCT04684940 · Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII
NCT03619863 · Hemophilia A With Inhibitor, Haemophilia A Without Inhibitor, and more
NCT04723693 · Hemophilia A With Inhibitor
NCT04303572 · Hemophilia A With Inhibitor
Beijing Children's Hospital
Beijing, Beijing Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions